Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?

about

Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?

Item

http://www.wikidata.org/entity/Q54974390

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Controversies in oncology: whi ...... ceptor-positive breast cancer?

@en

Controversies in oncology: whi ...... ceptor-positive breast cancer?

@nl

type

Item

label

Controversies in oncology: whi ...... ceptor-positive breast cancer?

@en

Controversies in oncology: whi ...... ceptor-positive breast cancer?

@nl

prefLabel

Controversies in oncology: whi ...... ceptor-positive breast cancer?

@en

Controversies in oncology: whi ...... ceptor-positive breast cancer?

@nl

P1476

Controversies in oncology: whi ...... ceptor-positive breast cancer?

@en

P2093

Giulia Viglietti

http://www.w3.org/2001/XMLSchema#string

P2860

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update

Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group.

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Adjuvant ovarian suppression in premenopausal breast cancer.

Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.

Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.

Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.

Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.

P304

e000350

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1136/ESMOOPEN-2018-000350

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Evandro de Azambuja

Matteo Lambertini

P577

2018-03-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29636992

http://www.w3.org/2001/XMLSchema#string

P932

5890055

http://www.w3.org/2001/XMLSchema#string